SterlingMedicalCenter.org Editorial Team | Telehealth Platform Analysis | Published April 28, 2026
Editorial Notice: This comparison is published for informational purposes only. It does not constitute medical advice or an endorsement of any platform. Prescription ED treatment requires clinician evaluation. SterlingMedicalCenter.org is not affiliated with MEDVi, Rugiet, or Hims, and does not receive compensation from any of these platforms for this analysis. See our Research Standards & Disclosures for full details.
The Decision Problem Most Men Are Actually Facing
If you have searched for MEDVi QUAD recently, you have probably noticed that the top results include a mix of product reviews, clinical analyses, and news coverage about the company's regulatory situation — and that the landscape of compounded telehealth ED platforms has expanded significantly enough that comparison becomes genuinely difficult. Hims has been in the ED telehealth space for years and is the default reference point. Rugiet introduced the compounded sublingual multi-ingredient model earlier than MEDVi. QUAD arrived with aggressive marketing and significant media attention in early 2026.
Choosing between them requires understanding where each platform fits in the treatment hierarchy — because these are not competing products for the same patient. They are designed for different clinical situations. Choosing the wrong one for where you are right now is at best a waste of money and at worst a step that skips appropriate clinical progression.
Hims: First-Line Single-Agent Therapy
Hims is the largest single-ingredient ED telehealth platform in the United States and offers generic sildenafil, tadalafil, and — through its Hims Hard Mints product — chewable sildenafil. Generic sildenafil from Hims (and comparable platforms like Ro, Lemonaid, and Keeps) costs approximately $2 to $10 per dose and has the most extensive evidence base of any ED medication.
What Hims is right for: Men who have not yet tried prescription PDE5 inhibitor therapy. Men who tried sildenafil at an inadequate dose or under incorrect conditions and concluded it didn't work, without having verified all the standard variables (dose ceiling, timing, food interaction). Men who are primarily cost-sensitive. Men who want a well-studied, widely prescribed, extensively monitored medication rather than a compounded formulation.
What Hims is not right for: Men who have genuinely exhausted single-agent PDE5 therapy at appropriate doses under proper conditions and found response insufficient or highly inconsistent. Men whose ED involves a central or psychological arousal dimension that sildenafil alone does not address. Men who need a longer active window than sildenafil provides and who have already tried daily tadalafil without adequate results.
The clinical bottom line on Hims: If you have not started here, start here. Generic sildenafil and tadalafil are not inferior treatments — they are appropriate first-line treatments with decades of safety and efficacy data behind them. Every clinical guideline on ED management places single-agent PDE5 inhibitor therapy as the first pharmacological step. The complexity and cost of multi-ingredient compounded formulations are only appropriate after this step has been properly completed.
Rugiet: Multi-Ingredient Sublingual — The Earlier Entrant
Rugiet's Ready formulation is a compounded sublingual multi-ingredient ED medication that predates MEDVi QUAD's arrival in the market. Its standard formulation typically combines sildenafil and tadalafil as its PDE5 components, with the option to include apomorphine. The key distinction from QUAD is that Rugiet does not include vardenafil as a third PDE5 inhibitor in its standard formulation — making the combination a two-PDE5 approach plus a central mechanism component, rather than QUAD's three-PDE5 approach.
Pricing: Rugiet generally runs approximately $150 to $180 per month for its standard formulation, higher than QUAD's $119 starting price. The company has an established track record and a longer history in the compounded sublingual ED space than MEDVi.
Clinical fit: Similar to QUAD — designed for men who have not achieved adequate results with single-agent therapy and want a multi-mechanism sublingual approach. The absence of vardenafil as a third PDE5 inhibitor means the combined PDE5 load is somewhat lower than QUAD, which may be a consideration for men with cardiovascular conditions requiring careful management. The apomorphine option addresses the same central arousal dimension that QUAD targets.
What Rugiet does better than QUAD right now: Track record. Rugiet has operated longer in this specific niche. The company does not carry the same April 2026 media scrutiny that MEDVi does. Men who are concerned about the MEDVi corporate and regulatory narrative — even though the warnings did not involve QUAD specifically — may prefer Rugiet's quieter operational profile. For a full breakdown of what the MEDVi controversy actually involved, see: MEDVi QUAD 2026 — is the 4-in-1 formula legit.
MEDVi QUAD: Four-Ingredient Compounded Sublingual
MEDVi QUAD's distinguishing features are the four-ingredient combination (sildenafil + tadalafil + vardenafil + apomorphine) and the sublingual liquid delivery format. It is currently the only widely marketed telehealth ED platform combining three PDE5 inhibitors in a single sublingual dose.
Pricing: Starts at $119/month, making it less expensive than Rugiet for comparable formulation complexity. Auto-renewing subscription; multiple consumer reports note billing friction. Confirm cancellation process before enrolling.
The three-PDE5 question: The FDA's prescribing information for sildenafil explicitly notes that combinations of PDE5 inhibitors “have not been studied” and “may further lower blood pressure.” This is not a finding that the combination is dangerous — it is a statement that the specific multi-drug combination has not been evaluated in clinical trials as a combined product. The prescribing clinician's role is to determine the appropriate dosing for each individual component, accounting for the aggregate vasodilatory effect. This is the purpose of the intake evaluation and why full medical history disclosure is essential. Men with more complex cardiovascular situations may find Rugiet's two-PDE5 model a more manageable starting point for multi-ingredient therapy.
The apomorphine differentiation: Both QUAD and Rugiet offer apomorphine as part of their formulation. For men whose ED has a significant central or psychological component — reduced desire, performance anxiety, inconsistent arousal despite adequate vascular function — this ingredient adds a mechanism that neither generic sildenafil nor generic tadalafil provides. This is QUAD's strongest clinical argument for the right patient.
Platform concerns: The April 2026 media coverage of MEDVi — the FDA warning letter (GLP-1 products, not QUAD), advertising practice concerns, and pending litigation involving clinical infrastructure partners — created questions about the company that are fair to weigh even if they did not directly involve the QUAD product line. MEDVi holds active LegitScript certification and has 11,400+ TrustPilot reviews. The concerns are real enough to understand; they are not conclusive enough to categorically disqualify the program for appropriate candidates.
BlueChew Gold and BraveRx: The 2026 Newcomers
The compounded ED telehealth market expanded meaningfully in 2026. Two newer entrants are worth understanding because they appear in the same SERP as QUAD and Rugiet.
BlueChew Gold combines sildenafil, tadalafil, vardenafil, and oxytocin. The oxytocin addition is its differentiator — marketed as supporting “emotional connection.” The clinical problem is bioavailability: oxytocin is a peptide that does not survive sublingual absorption into systemic circulation at meaningful concentrations. Multiple independent analyses of the formula have characterized it as functionally a three-ingredient product in practice. If three PDE5 inhibitors plus apomorphine (QUAD) or three PDE5 inhibitors plus oxytocin (BlueChew Gold) are the choice, the clinical literature supports apomorphine — it has published ED trial data. Oxytocin does not, for this route and indication.
BraveRx has a 4-in-1 formula structurally similar to QUAD — apomorphine plus PDE5 inhibitors. It is a newer entrant with less established market presence and fewer user reviews than QUAD or Rugiet. For men who want the QUAD-style formula but have concerns about MEDVi as a company after the April 2026 coverage, BraveRx is the most direct alternative to evaluate. Pricing and platform details should be verified directly, as they continue to evolve.
Ro Sparks is a sublingual compounded lozenge from Ro (a large, established telehealth platform) combining sildenafil and tadalafil — two PDE5 inhibitors, no apomorphine. It is generally priced lower than QUAD and benefits from Ro's longer operating history and broader platform infrastructure. For men who want sublingual delivery and a more established telehealth brand but do not need the central arousal mechanism, Ro Sparks is a credible two-ingredient alternative between single-agent platforms and the four-ingredient compounds.
Is Sublingual ED Medication Better Than Pills?
For most men starting ED treatment, standard oral tablets are the appropriate first step. They are well-studied, widely prescribed, low-cost, and have decades of safety and efficacy data. Sublingual delivery is not inherently better — it is pharmacologically different in ways that matter for a specific subset of patients.
Sublingual absorption bypasses first-pass hepatic metabolism, which produces faster onset and reduces the food-interaction problem that sildenafil tablets have. For men who consistently find that standard tablets either take too long or are unreliable after meals, sublingual delivery addresses those specific failure modes. For men who are satisfied with sildenafil or tadalafil tablets, moving to a more complex compounded sublingual formulation adds cost and regulatory complexity without a clear clinical reason.
The other distinction is the apomorphine component available in QUAD, Rugiet, and BraveRx — but not in standard single-ingredient platforms. Apomorphine targets the central nervous system arousal pathway, which oral PDE5 inhibitors do not reach. For men whose ED involves a psychological or desire-related component, that ingredient addition is clinically meaningful. For men with purely vascular ED who respond adequately to single-agent therapy, it adds side effect risk (primarily nausea) without a clear benefit.
The honest answer: sublingual multi-ingredient ED medication is better for a specific, defined patient profile. It is not better as a default starting point.
The Comparison Framework: How to Choose
Rather than declaring a winner, the honest framework for this comparison is a clinical decision tree:
Have you tried generic sildenafil or tadalafil at appropriate doses? If no — start with Hims, Ro, or a comparable single-agent platform. The cost difference alone ($10–20 per month vs. $119/month) makes this the obvious first step, and clinical guidelines support it.
Have you tried sildenafil and tadalafil correctly and found results consistently inadequate? If yes — a multi-ingredient sublingual formulation may be appropriate. Review the drug interaction and contraindication profile first (see: MEDVi QUAD drug interactions and safety considerations). If your cardiovascular situation is straightforward, QUAD's pricing advantage over Rugiet is a legitimate consideration. If your cardiovascular situation is more complex and you prefer a two-PDE5 rather than three-PDE5 combination as a starting point, Rugiet may be the more conservative first step into multi-ingredient therapy.
Is the central arousal dimension — desire, psychological initiation — a significant component of what you're experiencing? If yes — platforms that include apomorphine (both QUAD and Rugiet with apomorphine option) are more appropriate than generic single-agent platforms. For more on why the neurological arousal component matters in ED treatment, see: when sildenafil stops working — causes and next steps.
Are you sensitive to the corporate and regulatory narrative around MEDVi? That is a legitimate factor. Rugiet has a longer established track record and less recent media scrutiny. QUAD is less expensive. Both require the same informed approach to clinical evaluation and disclosure.
When None of These Are the Right Answer
Some men reading this comparison are beyond the appropriate range for any telehealth-based oral or sublingual ED treatment. If you are on nitrate medications, your cardiologist needs to be involved before any ED treatment decision. If you have recently had a heart attack, stroke, or unstable angina, cardiac stabilization comes first.
If you have tried both single-agent and multi-ingredient approaches without adequate response, intracavernosal injection therapy or vacuum erection devices address the vascular deficit through a different mechanism entirely — and an in-person urology consultation is the right next step, not another telehealth form.
The urge to find the right pill at the right price through a convenient telehealth process is understandable. It is the right solution for many men. It is not the right solution for all of them, and recognizing that distinction — and pursuing the right clinical path — matters more than any comparison between available platforms.
For the vascular and physiological context behind why ED progresses in ways that require different treatment approaches at different stages, see: vascular ED after 40 — why it happens and what changes it. For coverage of the supplement and viral remedy alternatives that the research does not support, see our earlier analyses: do gummies for ED actually work and the blue salt trick for ED.
This comparison is published by SterlingMedicalCenter.org for informational purposes only. It does not constitute an endorsement of any platform or medical advice. Pricing and platform details are subject to change; verify current terms directly with each provider. Prescription ED treatment requires clinician evaluation. Consult a qualified healthcare provider before starting any prescription treatment. SterlingMedicalCenter.org is not affiliated with MEDVi, Rugiet, Hims, or any healthcare organization.